This is a routine inducement grant with negligible dilution. No trading signal — monitor upcoming clinical catalysts for azenosertib (WEE1 inhibitor) in ovarian cancer for material moves.
Price Chart
Executive Summary
Zentalis granted 191,000 non-qualified stock options to two newly hired employees as an inducement for employment, with a $3.98 exercise price and four-year vesting. This is a routine equity inducement grant with no material financial impact.
Key Facts
- 191,000 stock options granted to two new employees under the 2022 Inducement Plan
- Exercise price of $3.98 per share, equal to the closing price on the grant date
- Options vest over four years: 25% at first anniversary, then monthly over three years
- Grant is an inducement material to employment per Nasdaq Listing Rule 5635(c)(4)
Financial Impact
191,000 options at $3.98 strike; dilution is immaterial relative to ~50M shares outstanding (est. <0.4%)
Risk Factors
- No clinical or financial data disclosed; stock moves on pipeline events, not this grant
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.52 (+31.98%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.52 (+29.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.52 (−32.80%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.52 (−36.20%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.52 (−36.84%) |
Apr 17, 2026 24w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.52 (−45.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access